8-K: CareDx Appoints R. Bryan Riggsbee to Board of Directors and Audit Committee Chair

CareDx has appointed R. Bryan Riggsbee to its Board of Directors and as Chairperson of the Audit and Finance Committee, effective March 11, 2024.

Summary

• CareDx has appointed R. Bryan Riggsbee to its Board of Directors as a Class II director, effective March 11, 2024.
• Mr. Riggsbee will also serve as the Chairperson of the Audit and Finance Committee.
• He previously served as Chief Financial Officer of Myriad Genetics and held senior finance positions at Laboratory Corporation of America (LabCorp) and General Electric.
• Mr. Riggsbee will receive an annual cash retainer of $45,000 for his board service and $20,000 for chairing the Audit Committee, payable quarterly.
• He will also receive stock options and restricted stock units with a grant date fair value of $100,000 each, contingent upon shareholder approval of a new equity incentive plan.
• Additionally, he will receive annual grants of stock options and restricted stock units with a grant date fair value of $150,000 each, vesting over one year.

Sentiment

Score: 8

Explanation: The appointment of an experienced financial executive is a positive development for the company, suggesting a focus on strong financial management and strategic growth. The compensation package is standard and aligns interests. The forward looking statements are standard and do not detract from the positive sentiment.

Positives

• The appointment of R. Bryan Riggsbee brings significant financial expertise to the CareDx Board.
• His experience as CFO of Myriad Genetics and in senior finance roles at LabCorp and General Electric is expected to benefit the company.
• Mr. Riggsbee's deep understanding of revenue cycle management in molecular diagnostics is seen as a valuable asset.
• The compensation structure for Mr. Riggsbee includes both cash and equity, aligning his interests with those of shareholders.

Risks

• The vesting of initial stock options and restricted stock units is contingent upon shareholder approval of a new equity incentive plan.
• The press release includes forward-looking statements that are subject to risks and uncertainties, which could cause actual results to differ materially.

Future Outlook

The company anticipates that Mr. Riggsbee's financial expertise and experience will contribute to the company's growth and mission of improving long-term outcomes for transplant patients. The company also notes that forward-looking statements are subject to risks and uncertainties.

Management Comments

• Michael Goldberg, CareDx Board Chairperson, stated that Bryan's financial expertise, operating background and deep understanding of revenue cycle management in molecular diagnostics will allow him to make meaningful contributions to the Board.
• Bryan Riggsbee stated he is thrilled to join the CareDx Board and looks forward to working with the company's leadership team to advance its mission.

Industry Context

This appointment is in line with the trend of companies in the molecular diagnostics and healthcare sectors seeking experienced financial leaders to guide their growth and strategic direction. Mr. Riggsbee's background in both molecular diagnostics and finance makes him a valuable addition to CareDx.

Comparison to Industry Standards

• The appointment of a seasoned financial executive like Mr. Riggsbee is a common practice among publicly traded companies, particularly in the healthcare and biotechnology sectors.
• His compensation package, including cash retainers and equity grants, is consistent with industry standards for non-employee directors and committee chairs.
• Companies like Myriad Genetics and LabCorp, where Mr. Riggsbee previously worked, are known for their strong financial management, suggesting that his experience aligns with best practices in the industry.
• The use of stock options and restricted stock units as part of director compensation is a standard practice to align the interests of directors with those of shareholders, similar to practices at companies like Exact Sciences and Invitae.

Management Changes

Related Party Transactions

• There are no family relationships between Mr. Riggsbee and any director or executive officer of the Company.
• Mr. Riggsbee has not engaged in any transaction that would be reportable as a related party transaction.

Stakeholder Impact

• Shareholders may view the appointment of an experienced financial executive positively, potentially increasing confidence in the company's financial management.
• Employees may benefit from the expertise and leadership of Mr. Riggsbee.
• The appointment is not expected to have a direct impact on customers, suppliers, or creditors.

Next Steps

• The company will seek shareholder approval for a new equity incentive plan to enable the vesting of Mr. Riggsbee's initial stock options and restricted stock units.
• Mr. Riggsbee will begin his service on the Board and as Chairperson of the Audit Committee, effective March 11, 2024.

Key Dates

Keywords

Board of Directors, Audit Committee, R. Bryan Riggsbee, Corporate Governance, Financial Officer, Stock Options, Restricted Stock Units, Compensation, Myriad Genetics, LabCorp, General Electric, Molecular Diagnostics, Transplant